Posted by Michael Wonder on 24 Aug 2016
NICE approves new cancer drugs for routine NHS use
24 August 2016 - Two cancer treatments, previously only available to patients through the Cancer Drugs Fund, will now be routinely available on the NHS.
NICE has approved bosutinib for leukaemia and pemetrexed for lung cancer for routine use on the NHS because the companies that market them lowered their prices.
Since April, NICE has been looking again at the cost and clinical effectiveness of drugs currently in the old Cancer Drugs Fund.
Previously both drugs had been available only if a person’s doctor applied through the Cancer Drugs Fund.
The discounted prices mean that both drugs are now considered value for money.
